{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T10:43:39Z","timestamp":1774608219949,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T00:00:00Z","timestamp":1662508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T00:00:00Z","timestamp":1662508800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s12072-022-10408-6","type":"journal-article","created":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T06:11:20Z","timestamp":1662531080000},"page":"1032-1034","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["MAFLD, patient-centred care, and APASL"],"prefix":"10.1007","volume":"16","author":[{"given":"Shiv K.","family":"Sarin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Eslam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-Gao","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han-Chieh","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob","family":"George","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masao","family":"Omata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,9,7]]},"reference":[{"key":"10408_CR1","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S2468-1253(19)30342-5","volume":"5","author":"SK Sarin","year":"2020","unstructured":"Sarin SK, Kumar M, Eslam M, George J, Al Mahtab M, Akbar SMF, et al. Liver diseases in the Asia\u2013Pacific region: a lancet gastroenterology & hepatology commission. Lancet Gastroenterol Hepatol. 2020;5:167\u2013228","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10408_CR2","doi-asserted-by":"publisher","first-page":"e573","DOI":"10.1016\/j.cgh.2021.02.030","volume":"20","author":"J Liu","year":"2022","unstructured":"Liu J, Ayada I, Zhang X, Wang L, Li Y, Wen T, et al. Estimating global prevalence of metabolic dysfunction-associated fatty liver disease in overweight or obese adults. Clin Gastroenterol Hepatol. 2022;20:e573\u2013e582","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10408_CR3","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s12072-020-10094-2","volume":"14","author":"M Eslam","year":"2020","unstructured":"Eslam M, Sarin SK, Wong VW-S, Fan J-G, Kawaguchi T, Ahn SH, et al. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int. 2020;14:889\u2013919","journal-title":"Hepatol Int"},{"issue":"9","key":"10408_CR4","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1210\/clinem\/dgac321","volume":"107","author":"KE Chan","year":"2022","unstructured":"Chan KE, Koh TJL, Tang ASP, Quek J, Yong JN, Tay P, Tan DJH, et al. Global prevalence and clinical characteristics of metabolic associated fatty liver disease. A meta-analysis and systematic review of 10,739,607 individuals. J Clin Endocrinol Metab. 2022;107(9):2691\u20132700","journal-title":"J Clin Endocrinol Metab"},{"key":"10408_CR5","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.tips.2019.05.002","volume":"40","author":"M Eslam","year":"2019","unstructured":"Eslam M, George J. Genetic insights for drug development in NAFLD. Trends Pharmacol Sci. 2019;40:506\u2013516","journal-title":"Trends Pharmacol Sci"},{"key":"10408_CR6","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S2468-1253(20)30294-6","volume":"6","author":"G Shiha","year":"2021","unstructured":"Shiha G, Korenjak M, Eskridge W, Casanovas T, Velez-Moller P, H\u00f6gstr\u00f6m S, et al. Redefining fatty liver disease: an international patient perspective. Lancet Gastroenterol Hepatol. 2021;6:73\u201379","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10408_CR7","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","volume":"158","author":"M Eslam","year":"2020","unstructured":"Eslam M, Sanyal AJ, George J, Sanyal A, Neuschwander-Tetri B, Tiribelli C, et al. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158:1999\u20132014 (e1991)","journal-title":"Gastroenterology"},{"key":"10408_CR8","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","volume":"73","author":"M Eslam","year":"2020","unstructured":"Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73:202\u2013209","journal-title":"J Hepatol"},{"key":"10408_CR9","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1016\/S2468-1253(21)00183-7","volume":"6","author":"M Eslam","year":"2021","unstructured":"Eslam M, Alkhouri N, Vajro P, Baumann U, Weiss R, Socha P, et al. Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement. Lancet Gastroenterol Hepatol. 2021;6:864\u2013873","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10408_CR10","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1111\/liv.13397","volume":"37","author":"S Petta","year":"2017","unstructured":"Petta S, Eslam M, Valenti L, Bugianesi E, Barbara M, Camm\u00e0 C, et al. Metabolic syndrome and severity of fibrosis in nonalcoholic fatty liver disease: an age-dependent risk profiling study. Liver Int. 2017;37:1389\u20131396","journal-title":"Liver Int"},{"key":"10408_CR11","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S2468-1253(20)30213-2","volume":"6","author":"G Shiha","year":"2021","unstructured":"Shiha G, Alswat K, Al Khatry M, Sharara AI, \u00d6rmeci N, Waked I, et al. Nomenclature and definition of metabolic-associated fatty liver disease: a consensus from the Middle East and north Africa. Lancet Gastroenterol Hepatol. 2021;6:57\u201364","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10408_CR12","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S2468-1253(20)30340-X","volume":"6","author":"N Mendez-Sanchez","year":"2021","unstructured":"Mendez-Sanchez N, Arrese M, Gadano A, Oliveira CP, Fassio E, Arab JP, et al. The Latin American Association for the Study of the Liver (ALEH) position statement on the redefinition of fatty liver disease. Lancet Gastroenterol Hepatol. 2021;6:65\u201372","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10408_CR13","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1016\/j.jhep.2021.01.015","volume":"74","author":"CW Spearman","year":"2021","unstructured":"Spearman CW, Desalegn H, Ocama P, Awuku YA, Ojo O, Elsahhar M, et al. The sub-Saharan Africa position statement on the redefinition of fatty liver disease: from NAFLD to MAFLD. J Hepatol. 2021;74:1256\u20131258","journal-title":"J Hepatol"},{"key":"10408_CR14","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.jhep.2021.12.020","volume":"77","author":"N M\u00e9ndez-S\u00e1nchez","year":"2022","unstructured":"M\u00e9ndez-S\u00e1nchez N, Maris-Gil S, Alonso-Rivera CG. Latin American Association of Pediatrics (ALAPE) endorses the MAFLD definition of fatty liver disease. J Hepatol. 2022;77:249","journal-title":"J Hepatol"},{"key":"10408_CR15","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.jhep.2021.05.003","volume":"75","author":"Y Nan","year":"2021","unstructured":"Nan Y, An J, Bao J, Chen H, Chen Y, Ding H, et al. The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease. J Hepatol. 2021;75:454\u2013461","journal-title":"J Hepatol"},{"key":"10408_CR16","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/S2468-1253(22)00062-0","volume":"7","author":"N M\u00e9ndez-S\u00e1nchez","year":"2022","unstructured":"M\u00e9ndez-S\u00e1nchez N, Bugianesi E, Gish RG, Lammert F, Tilg H, Nguyen MH, et al. Global multi-stakeholder endorsement of the MAFLD definition. Lancet Gastroenterol Hepatol. 2022;7:388\u2013390","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10408_CR17","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/S2468-1253(21)00132-1","volume":"6","author":"M Eslam","year":"2021","unstructured":"Eslam M, Ahmed A, Despr\u00e9s J-P, Jha V, Halford JC, Chieh JTW, et al. Incorporating fatty liver disease in multidisciplinary care and novel clinical trial designs for patients with metabolic diseases. Lancet Gastroenterol Hepatol. 2021;6:743\u2013753","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10408_CR18","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1097\/MOG.0000000000000823","volume":"38","author":"J Alharthi","year":"2022","unstructured":"Alharthi J, Gastaldelli A, Cua IH, Ghazinian H, Eslam M. Metabolic dysfunction-associated fatty liver disease: a year in review. Curr Opin Gastroenterol. 2022;38:251\u2013260","journal-title":"Curr Opin Gastroenterol"},{"key":"10408_CR19","doi-asserted-by":"publisher","first-page":"3018","DOI":"10.1111\/liv.14675","volume":"40","author":"S Yamamura","year":"2020","unstructured":"Yamamura S, Eslam M, Kawaguchi T, Tsutsumi T, Nakano D, Yoshinaga S, et al. MAFLD identifies patients with significant hepatic fibrosis better than NAFLD. Liver Int. 2020;40:3018\u20133030","journal-title":"Liver Int"},{"key":"10408_CR20","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1111\/hepr.13685","volume":"51","author":"T Tsutsumi","year":"2021","unstructured":"Tsutsumi T, Eslam M, Kawaguchi T, Yamamura S, Kawaguchi A, Nakano D, et al. MAFLD better predicts the progression of atherosclerotic cardiovascular risk than NAFLD: generalized estimating equation approach. Hepatol Res. 2021;51:1115\u20131128","journal-title":"Hepatol Res"},{"key":"10408_CR21","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1016\/j.jhep.2020.12.035","volume":"74","author":"Y Fouad","year":"2021","unstructured":"Fouad Y, Gomaa A, Semida N, Ghany WA, Attia D. Change from NAFLD to MAFLD increases the awareness of fatty liver disease in primary care physicians and specialists. J Hepatol. 2021;74:1254\u20131256","journal-title":"J Hepatol"},{"key":"10408_CR22","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/j.jhep.2021.01.022","volume":"74","author":"SA Alem","year":"2021","unstructured":"Alem SA, Gaber Y, Abdalla M, Said E, Fouad Y. Capturing patient experience: a qualitative study of change from NAFLD to MAFLD real-time feedback. J Hepatol. 2021;74:1261\u20131262","journal-title":"J Hepatol"},{"key":"10408_CR23","doi-asserted-by":"publisher","first-page":"150","DOI":"10.3350\/cmh.2021.0310","volume":"28","author":"T Kawaguchi","year":"2022","unstructured":"Kawaguchi T, Tsutsumi T, Nakano D, Eslam M, George J, Torimura T. MAFLD enhances clinical practice for liver disease in the Asia\u2013Pacific region. Clin Mol Hepatol. 2022;28:150","journal-title":"Clin Mol Hepatol"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-022-10408-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-022-10408-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-022-10408-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T07:35:46Z","timestamp":1664523346000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-022-10408-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,7]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["10408"],"URL":"https:\/\/doi.org\/10.1007\/s12072-022-10408-6","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,7]]},"assertion":[{"value":"25 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}